A diabetes drug may beat costly shots for patients with a rare genetic condition, according to a Rutgers Health study.

A weekly diabetes medication may replace painful daily hormone injections for patients with congenital generalised lipodystrophy (CGL). Early findings suggest that tirzepatide – used for diabetes and ...

A recent survey found that more than half of people living with Type 1 diabetes say the condition has an impact on their ...

A recent survey found that more than half of adults living with Type 1 diabetes believe the condition limits their ability to be spontaneous ...

Innogen, a Shanghai-based medical technology company, announced that its independently developed, human-derived, ...

Discover how tirzepatide, a diabetes drug, offers hope for congenital generalized lipodystrophy (CGL) treatment, potentially ...

A new survey has found that Type 1 diabetes can affect everyday decisions for nearly a third of those diagnosed ...

Insulin pumps and CGMS provide greater flexibility, improved blood sugar control, and better quality of life for children and ...

A human-derived, ultra-long-acting GLP-1 injection independently researched and developed by Innogen, a Shanghai-based ...

Desmopressin is approved in various forms, but these do not meet the paediatric need for precise, titratable and small doses.

Diabetes UK estimated a further 6.3 million people are living with non-diabetic hyperglycaemia, some of whom do not know they ...

Rutgers Health researchers have found that a weekly injection of diabetes medication could replace painful daily hormone shots for people with a rare genetic form of lipodystrophy that leaves patients ...